Measuring infliximab and adalimumab drug and antibodies in Crohn's disease and ulcerative colitis
No Thumbnail Available
Authors
Perry, Mandy
McDonald, Timothy J.
Cudmore, Adrian
Ahmad, Tariq
Journal
Clinical Laboratory International
Type
Journal Article
Publisher
Clinical Laboratory International
DOI
Rights
The anti-TNF therapies infliximab and adalimumab have revolutionized the treatment of inflammatory bowel disease, being very effective in many patients. Some patients experience problems such as loss of response, which is associated with production of antibodies to the therapy. Measuring trough drug and antibody concentrations may direct patient management in future.
Citation
Measuring infliximab and adalimumab drug and antibodies in Crohn's disease and ulcerative colitis. 2015. Clinical Laboratory International